The prevalence of bacteria with resistance to most clinically useful antibiotics is growing in many parts of the world. Reports of infections caused by so-called pan-resistant bacteria demonstrate the difficulties, which clinicians encounter during treatment of patients with such infections. Sometimes we are running out of treatment options.
For some years the problem of antibiotic resistance in nosocomial pathogens was more pronounced in southern European countries than in Middle or Northern Europe. As recently published studies show, antibiotic resistance has become an important problem in the middle and northern parts of Europe as well. For example, the proportion of E. coli with resistance to third generation cephalosporins and ciprofloxacin has increased over the course of four years in German intensive care units [1] .
Among many gramnegative pathogens, Enterobacter species and Acinetobacter species have been found to contribute to the problem of multiresistance in a major way. Development of resistance is associated with the use of third generation cephalosporins or the prolonged use of perioperative antibiotic prophylaxis [2] . Other risk factors for colonization or infection with multiresistant bacteria such as Enterobacteriaceae with production of extended-spectrum betalactamases include the presence of an indwelling urinary catheter or residence in a nursing home [3] . As long as there are options to switch from one class of antibiotics to another, the resistance "problem" can still be overcome. In the past, new drugs were able to help us out after we "lost" older antibiotics, e.g. amoxicillin, to resistance.
As the number of newly developed antibiotics is quite low, we are forced to look back and dig deep in the pharmacy closet to come up with old antibiotics, which have been forgotten during the luxurious years of abundant development of new antibiotics.
Polymyxins such as colistin are among these "old" antibiotics, which were relegated to the back of the shelf due to toxicity. Now they stand ready to help us treat patients with infections caused by multiresistant bacteria. Very few "modern" clinicians are experienced in their use. As published data on their use is distributed among various journals, a review on their clinical use most likely will be helpful in times of need. In this issue of INFECTION Falagas and Kasiakou summarize key information on the local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections [4] .
Based on personal experience with a few cases I can say that this treatment works. Let's hope that we can all say the same in 5 or 10 years, as most likely we will still need the "old drugs".
